‘Break-point Checkerboard Plate’ for screening of appropriate antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa

References

• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis 2002; 34: 634–40
   PubMed Web of Science ®Google Scholar
• Cappelletty DM, Rybak MJ. Comparison of methodologies for synergy testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 677–83
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edn: Approved standard M7-A6. NCCLS, VillanovaPA, USA. 2004.
   Google Scholar
• Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 1999; 33: 960–7
   PubMed Web of Science ®Google Scholar
• Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3: 108–27
   PubMed Web of Science ®Google Scholar
• San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004; 48: 168–71
   PubMed Web of Science ®Google Scholar
• Bonapace CR, White RL, Friedrich LV, Bosso JA. Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with E-test, time-kill, and checkerboard methods. Diagn Microbiol Infect Dis 2000; 38: 43–50
   PubMed Web of Science ®Google Scholar
• Tunney MM, Scott EM. Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitro. J Microbiol Methods 2004; 57: 107–14
   PubMed Web of Science ®Google Scholar
• Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002; 46: 1105–7
   PubMed Web of Science ®Google Scholar
• Okazaki M, Suzuki K, Asano N, Araki K, Shukuya N, Egami T, et al. Effectiveness of phosphomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J Infect Chemother 2002; 8: 37–42
   PubMedGoogle Scholar
• Oie S, Uematsu T, Sawa A, Mizuno H, Tomita M, Ishida S, et al. In vitro effects of combinations of antipseudomonal agents against 7 strains of multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2003; 52: 911–4
   PubMed Web of Science ®Google Scholar
• Erdem I, Kucukercan M, Ceran N. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Chemotherapy 2003; 49: 294–7
   PubMed Web of Science ®Google Scholar
• Sader HS, Huynh HK, Jones RN. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against Gram-negative bacilli. Diagn Microbiol Infect Dis 2003; 47: 547–50
   PubMed Web of Science ®Google Scholar
• Song W, Woo HJ, Kim JS, Lee KM. In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003; 21: 8–12
   PubMed Web of Science ®Google Scholar
• Erdem I, Kaynar-Tascioglu J, Kaya B, Goktas P. The comparison of the in vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Int J Antimicrob Agents 2002; 20: 384–6
   PubMed Web of Science ®Google Scholar
• Pendland SL, Messick CR, Jung R. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2002; 42: 75–8
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11–25
   PubMed Web of Science ®Google Scholar
• Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001; 7: 434–40
   PubMedGoogle Scholar
• Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47: 905–9
   PubMed Web of Science ®Google Scholar
• Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45: 781–5
   PubMed Web of Science ®Google Scholar
• Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004; 48: 753–7
   PubMed Web of Science ®Google Scholar
• Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008–11
   PubMed Web of Science ®Google Scholar
• Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37: 154–60
   PubMed Web of Science ®Google Scholar
• Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 2004; 54: 566–9
   PubMed Web of Science ®Google Scholar
• Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001; 41: 645–54
   PubMed Web of Science ®Google Scholar
• Ostenson RC, Fields BT, Nolan CM. Polymyxin B and rifampin: new regimen for multiresistant Serratia marcescens infections. Antimicrob Agents Chemother 1977; 12: 655–9
   PubMed Web of Science ®Google Scholar
• Tascini C, Menichetti F, Bozza S, Del Favero A, Bistoni F. Evaluation of the activities of 2-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother 1998; 42: 270–1
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 2003; 15: 235–8
   PubMed Web of Science ®Google Scholar
• Tascini C, Gemignani G, Ferranti S, Tagliaferri E, Leonildi A, Lucarini A, et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother 2004; 16: 282–7
   PubMed Web of Science ®Google Scholar